Sidec社後援 特別フォーラム & ディナー

タンパク質のトモグラフィーについての世界初の会合となります。

2008年 5月1日 (木) 1:00-6:00pm, Boston InterContinental Hotel

The Executive Forum will focus on the unique biological information obtained in situ and in vitro by Protein Tomography to elucidate the
interaction of antibodies with drug targets at the molecular level. We will discuss the role of Protein Tomography to provide essential data for epitope mapping, IP, and how to resolve issues in the discovery phase. We will focus on how this insight impacts the decision-making process for the development of bio-therapeutics. Watch the Sidec Webinar

Sidec's Executive Forum will be held during the PEGS Summit on May 1 from 1-6pm with dinner to follow at 6:30pm. The audience will
be comprised of executive-level members of the therapeutic antibody discovery and development industry.

To submit a presentation, contact robert.england@sidec.com
For more information, visit www.sidec.com

Bio-therapeutic R&D is hampered by inconclusive evidence of how the drug actually operates on the target. Sidec research and Protein
Tomography™ solves this with unique insights at the molecular level for antibody development projects.
Sidec research collaborations provide information for:

• Prioritization of the most promising antibodies for development
• Epitope mapping
• Protection of IP
• Promotion of therapeutic products to licensees

* こちらのコースへの出席に際しては別途お申し込みが必要となります。

Preliminary Agenda

Protein Tomography: Enabling Technology for Therapeutic Antibody Development
Fritz Frickel, PhD, Industry Analyst
Despite the wealth of information and strategies arising from in silico molecular modeling and screening, there is still a glaring lack of information on the molecular mechanisms of action between drug and target. I will illustrate the potential of deeper molecular insight and indicate where, when and how I envisage its impact in the drug discovery process. 

Transforming the Selection Process and IP Opportunities in Antibody Development
Hans Johansson, CEO Sidec AB
Maximum value from antibody development can be derived from unique and non-ambiguous IP. New insights into epitope mapping, validation and binding can radically improve the development process and create new IP opportunities.

Hans Johansson is CEO of Sidec AB since 2004. From a background in chemical engineering, his career in the life sciences supply industry includes positions as VP global marketing at Pharmacia Biotechnology AB, VP Applied Genomics at AmershamPharmacia AB, CEO Personal Chemistry AB, CEO Pyrosequencing AB and VP Genomics at Biotage AB.

Does Unambiguous Proof of a Drug Epitope Permit Enhanced IP Protection?
Kathleen Madden Williams, Ph.D., JD, Edwards Agnell Palmer & Dodge LLP
Present day patent protection on antibodies has entered an ever-narrowing tunnel, and many current patents are limited to a specific antibody sequence or a set of CDR sequences. This level of protection most often does not prevent competition by slightly different CDR or antibody sequences. The ideal antibody patent protection is limited to the antigen specificity, but rarely do we see such patents issuing now. How can one narrow the legal void between protection of an antibody specific for an antigen and an antibody having a specific sequence? Is there a gold standard by which to distinguish an antibody and thereby obtain meaningful patent protection?

Kathleen Williams is an intellectual property attorney specializing in life sciences IP and a partner at Edwards, Angell Palmer & Dodge LLP. She advises as to the strategic use of IP to obtain patent protection, as well as positioning research and commercial activities with respect to third party patents.